FDA Approved: VABRINTY — Supplemental Application (URONOVA PHARMACEUTICALS, INC.)

View source ↗

Summary

FDA approved a supplemental application for VABRINTY (leuprolide acetate) from Uronova Pharmaceuticals to modify the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Precocious Puberty
• Endometriosis
• Prostate Cancer
• Uterine Fibroids

Drugs mentioned

• VABRINTY (LEUPROLIDE ACETATE)

Snippet

SUPPL AP for VABRINTY (LEUPROLIDE ACETATE)